The Australian: Race submits key ethics application for phase I cancer trial
Conducted in two stages, the Phase 1 clinical trial will examine the safety and tolerability of the reformulated bisantrene, RC220, in particular the drug’s cardioprotective ability when used in combination with doxorubicin, a form of anthracycline commonly used in chemotherapy. The ethics submission is a milestone after a year’s preparation, with the first patient recruitment expected to take place in Q1 2025.
Read the full article via this link.
Watch the full interview with CEO and Managing Director Dr Daniel Tillet.
